The siRNA was packaged with cholesterol‐modified polymeric CXCR4 inhibitor (PCX) for tumor‐targeted delivery during tumor growth.[22] Because the knockdown efficiency of Inhba siRNA was influenced by cell confluence(Figure S2B, Supporting Information), we had the initial siRNA injection on day 4 (D4) of implantation and had three injections every other day from D11 as most of the pancreas became tumor at D12 as detected by ultrasound imaging (Figure S3, Supporting Information). Here, INHBA is linked to neoplasm.